FDA Clears First Nebulized LAMA Inhaler for COPD


eMediNexus    08 December 2017

The US Food and Drug Administration (FDA) has approved glycopyrrolate inhalation solution 25 mcg twice daily for maintenance treatment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. This is the first nebulized long-acting muscarinic antagonist (LAMA) approved by the FDA for the treatment of COPD.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.